EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 115 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Beauty, Healing and Space January 27, 2021 ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 Exercise of Any Intensity Found to Provide Similar Benefits in Cancer... February 10, 2021 Load more HOT NEWS Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared... Olaparib approved for 800 prostate and breast cancer patients in England Easy Meals at Home
